were among the best-performing health-related stocks Tuesday, rising 7% after the company raised its sales forecast for its Selenia digital-mammography systems.
The maker of medical-imaging products now expects to sell 130 Selenia systems during the third quarter, up from an earlier forecast of 120. The company also said that it expects to sell 140 units during the fourth quarter, up from an earlier view of 122 units. For all of fiscal 2006, the company now sees sales of 478 systems. "We are winning new customers, as well as additional business from existing customers," Hologic said. "We remain committed to meeting the technological design and quality our customers have come to expect from us while at the same time providing value to our shareholders." Shares were trading up $2.61 to $38.13.
rose 2% after the health insurer backed its 2006 earnings guidance. The company continues to project earnings of $2.82 to $2.88 a share. Analysts polled by Thomson First Call project earnings of $2.80 a share. The company, which disclosed the updated guidance in a
Securities and Exchange Commission
filing, said its management team plans to reaffirm guidance at scheduled meetings with investors at various times during June. Shares were trading up $1.07 to $50.97.
rose 3% after the company said a federal court in California dismissed a lawsuit filed by
( TRCA) that alleged unfair business practices. The complaint, which was filed in the U.S. District Court for the Northern District of California, alleged that Insmed made false and misleading statements about Tercica. "We are pleased that the Court ruled that Tercica's complaint was without merit and upheld Insmed's right to inform the investment community about our product development activities related to Iplex without violating the Lanham Act," Insmed said in a press release. Insmed now plans to seek fees and costs related to defending itself against the suit.
Insmed said Tercica has filed a similar lawsuit in the Virginia courts, alleging much of the same information that was contained in the dismissed lawsuit filed in California. "As with the California case," the company said, "Insmed will vigorously defend its position and right to inform the investment community about product development activities." Shares of Insmed were trading up 4 cents to $1.45, while shares of Tercica were down 15 cents, or 4%, to $3.88.
rose 1% after the biotech company said its treatment for follicular non-Hodgkin's lymphoma received fast-track status from the Food and Drug Administration. "Securing fast track designation for MyVax personalized immunotherapy in advance of the phase III study interim analysis this summer is especially meaningful and puts us one step further down our pathway toward commercialization," Genitope said. Shares were up 8 cents to $6.50.
slipped Tuesday, even though the company posted positive results from a trial studying its weight-loss drug. The company said that data from its phase IIb trial of lorcaserin hydrochloride showed statistically significant average weight loss and reductions in other physical measures when compared to a placebo. "Based on the strength of these data," Arena said, "we are currently in discussions with the FDA about initiating a phase III trial of lorcaserin in obese patients later this year." Still, Arena shares recently were lower by 22 cents to $12.54.
Other health care volume movers included
, down 8 cents to $23.21;
, down 63 cents to $18.78;
Johnson & Johnson
, unchanged at $61.38;
, up 50 cents to $67.39;
, down 41 cents to $15.07;
, up 50 cents to $33.87;
( DNA), down 28 cents to $78.82;
, down 26 cents to $44.90; and
, up 42 cents to $24.90.